Similar articles

• Comment on: A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan.

  Shirota S, Shirai T, Mori K, Inoue J, Sato H, Ishii T, Fujii H. Shirota S, et al. Rheumatology (Oxford). 2024 Apr 2;63(4):e149-e150. doi: 10.1093/rheumatology/kead561. Rheumatology (Oxford). 2024. PMID: 37878792 No abstract available.
• Cutaneous manifestations of microscopic polyangiitis successfully controlled with avacopan alone.

  Kamiya S, Koizumi H, Suzuki Y, Imai S, Yamashita Y, Ogawa-Momohara M, Takeichi T, Muro Y, Yasuda K, Akiyama M. Kamiya S, et al. J Dermatol. 2023 Jul;50(7):e206-e207. doi: 10.1111/1346-8138.16726. Epub 2023 Jan 18. J Dermatol. 2023. PMID: 36651057 No abstract available.
• Avacopan's potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis.

  Taniguchi T, Hiwa R, Shoji M, Yamaguchi E, Shirakashi M, Onizawa H, Tsuji H, Kitagori K, Nakashima R, Akizuki S, Onishi A, Yoshifuji H, Tanaka M, Morinobu A. Taniguchi T, et al. Mod Rheumatol Case Rep. 2024 Jul 8;8(2):314-317. doi: 10.1093/mrcr/rxae016. Mod Rheumatol Case Rep. 2024. PMID: 38564324
• Avacopan: First Approval.

  Lee A. Lee A. Drugs. 2022 Jan;82(1):79-85. doi: 10.1007/s40265-021-01643-6. Drugs. 2022. PMID: 34826105 Review.
• [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].

  Holle JU, Hellmich B, Moosig F. Holle JU, et al. Z Rheumatol. 2022 May;81(4):280-285. doi: 10.1007/s00393-021-01154-5. Epub 2022 Jan 21. Z Rheumatol. 2022. PMID: 35061059 Review. German.